Table 6 Top licensing deals in 2019

From: Europe’s biotech renaissance

Companies (role)DealDate announcedUpfront cash ($ millions)
Amgen (licensor)Amgen partners with BeiGene to expand oncology presence in China31 October2,700
BeiGene (licensee)
AstraZeneca (licensee)Daiichi grants AstraZeneca worldwide commercialization and development rights to trastuzumab deruxtecan (DS-8201) to treat cancer28 March1,350
Daiichi Sankyo (licensor)
Roche (licensee)Sarepta grants Roche exclusive, ex-US rights to develop and commercialize SRP-9001 to treat Duchenne muscular dystrophy23 December750
Sarepta Therapeutics (licensor)
Alnylam Pharmaceuticals (licensor)Alnylam and Regeneron partner in a five-year deal to discover, develop and commercialize RNAi therapeutics8 April400
Regeneron Pharmaceuticals (licensee)
GlaxoSmithKline (licensee)Merck KGaA grants GlaxoSmithKline rights to co-develop and co-commercialize bintrafusp alfa to treat cancer5 February343.6
Merck KGaA (licensor)
Adaptive Biotechnologies (licensor)Adaptive Biotechnologies partners with Roche’s Genentech unit to develop personalized and off-the-shelf T cell therapies to treat cancer4 January300
Genentech (licensee)
Roche (other)
Akcea Therapeutics (licensor)Akcea Therapeutics grants Pfizer exclusive, worldwide rights to develop and commercialize AKCEA-ANGPTL3-LRx to treat cardiovascular and metabolic diseases7 October250
Ionis Pharmaceuticals (other)
Pfizer (licensee)
AstraZeneca (licensor)Cheplapharm Arzneimittel purchases AstraZeneca’s commercial rights to heart failure and hypertension drugs Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil and hydrochlorothiazide) in Europe1 October243
Cheplapharm Arzneimittel (licensee)
Clinigen (licensee)Novartis grants Clinigen exclusive, US rights to Proleukin (aldesleukin), giving Clinigen worldwide rights to the IL-2 therapy13 February180
Novartis (licensor)
AstraZeneca (licensor)Cheplapharm Arzneimittel purchases AstraZeneca’s commercial rights to schizophrenia and bipolar disorder drugs Seroquel (quetiapine) and Seroquel XR in Europe and Russia30 October178
Cheplapharm Arzneimittel (licensee)
Dicerna Pharmaceuticals (licensor)Dicerna partners with Novo Nordisk to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s GalXC RNAi platform technology18 November175
Novo Nordisk (licensee)
CRISPR Therapeutics (licensor)CRISPR grants Vertex exclusive, worldwide rights to its current and future intellectual property covering CRISPR–Cas9 technology, endonucleases, single- and double-cut guide RNAs and adeno-associated viral vectors to develop Duchenne muscular dystrophy and myotonic dystrophy type 1 gene editing therapies6 June175
Vertex Pharmaceuticals (licensee)
  1. Source: BCIQ BioCentury Online Intelligence